A Phase 1 interventional study of Dolutegravir dispersible tablet and Dolutegravir oral suspension in HIV Infections, sponsored by ViiV Healthcare. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-31.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing dolutegravir in HIV Infections — 7 open to participants now, 9 under way, 4 of them phase 3. Dolutegravir · HIV Infections.
Among the 55 studies testing dolutegravir in HIV Infections, this one is the 48th largest by enrollment, is one of 8 that started in 2019, is one of 7 in phase 1, and was the 35th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →7 of the 55 studies testing dolutegravir in HIV Infections are open now, in 12 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in Romania, South Africa, Uganda
José Antonio Mata Marín · Sites in Mexico
Ages 18–70
Instituto Mexicano del Seguro Social · Sites in Mexico
Ages 18+
José Antonio Mata Marín · Sites in Mexico
Ages 18–70 · Men only
ViiV Healthcare · Sites in United States
Ages 6–12
By country, each count listing its studies:
Dolutegravir: first FDA approval 2013 (TIVICAY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 15 · Phase 3 24 · Phase 4 11
First in 2009; this study’s year is marked. 8 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 126 across the 55 interventional studies. Of the 43 that completed or were terminated, 26 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 55 have an industry lead sponsor. The 10 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 176th largest by enrollment of the 210 interventional ones that give a count, is one of 14 that started in 2019, is one of 83 in phase 1, and was the 199th registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
1 of the studies testing dolutegravir in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07031063Instituto Mexicano del Seguro SocialSafety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 55 studies testing dolutegravir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
This is an open-label, single-center, single dose, non-randomized, sequential, fixed-sequence study, which will evaluate pharmacokinetics (PK) of dolutegravir (DTG) in healthy adult subjects. The study will contain 6 periods with five prototype liquid formulations for evaluation in fasted state. In period 1, 2 and 3 single reference dose of 2 dispersible tablets of 5 milligram DTG will be administered and at least 2 liquid prototype DTG formulations (containing a target total dose of 10mg DTG). There will be a wash-out period of 7 days between each period. In period 4 through 6, there would be options to evaluate additional prototype liquid formulations. The total duration of study will be up to 17 weeks. DTG has been found to be safe and effective in adults infected with human immunodeficiency virus (HIV). DTG dispersible tablets have been developed primarily for use in children from 4 weeks to 6 years of age, and a DTG liquid formulation are is being developed to study the appropriate dose needed for the HIV-exposed and infected neonatal population in the first four weeks of life. Approximately 18 subjects will be enrolled in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subject will receive a prototype equivalent to DTG 10 mg liquid formulation in period 1, a prototype equivalent to DTG 10 mg liquid formulation in period 2, a DTG 10 mg dispersible tablet in Period 3, each period will be separated by washout period of \>= 7 days, if required a prototype equivalent to DTG 10 mg liquid formulation in period 4, a prototype equivalent to DTG 10 mg liquid formulation in period 5, and a prototype equivalent to DTG 10 mg liquid formulation in period 6 will be evaluated.
Drug: Dolutegravir dispersible tablet · Drug: Dolutegravir oral suspension · Drug: Dolutegravir oral solution
DTG will be available as an oral tablet with dosing strength of 5 mg 2 tablet will be dispersed in water will be administered orally for prescribed regimen.
DTG will be available as an oral suspension with dosing strength of 5 mg per milliliter (ml) or 2 mg per ml with miglyol 812N or ethyl cellulose in miglyol 812N as vehicle for suspension administered orally for prescribed regimen.
DTG will be available as an oral solution with dosing strength of 2 mg per ml will be administered orally for prescribed regimen.
Area Under the Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Time Point (AUC[0-t]) for DTG
Blood samples were collected at indicated time points and pharmacokinetic (PK) analysis was performed. PK parameters were determined by non-compartmental methods.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose
AUC From Time Zero to Infinity (AUC[0-inf]) for DTG
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose
Maximum Observed Concentration (Cmax) for DTG
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose
Absorption Lag Time (Tlag) Following Administration of DTG
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose
Time of Maximum Observed Concentration (Tmax) Following Administration of DTG
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose
Time of Last Quantifiable Concentration (Tlast) Following Administration of DTG
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose
Elimination Half-life (t½) Following Administration of DTG
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose
Apparent Elimination Rate Constant (Lambda z) Following Administration of DTG
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose
Percentage of AUC(0-inf) Extrapolated (%AUCex) Following Administration of DTG
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48, and 72 hours post-dose
AUC From Time Zero to 24 Hours (AUC[0-24]) Following Administration of DTG
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, and 24 hours post-dose
AUC From Time Zero to 72 Hours (AUC[0-72]) Following Administration of DTG
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Apparent Oral Clearance (CL/F) Following Administration of DTG
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Last Quantifiable Concentration (Ct) Following Administration of DTG
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
Time frame: Pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Apparent Oral Volume of Distribution (Vz/F) Following Administration of DTG
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
Time frame: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3,3.5, 4, 5, 6, 8, 12, 16, 24, 48 and 72 hours post-dose
Concentration at 24hours Post-dose (C24) Following Administration of DTG
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
Time frame: 24 hours
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
SBP and DBP was measured in a supine position after at least 5 minutes of rest for the participant in a quiet setting without any distractions using a completely automated device. Day -1 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specific time point value.
Time frame: Baseline (Day -1) and Day 4
Change From Baseline in Pulse Rate
Pulse rate was measured in a supine position after at least 5 minutes of rest for the participant in a quiet setting without any distractions using a completely automated device. Day -1 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specific time point value.
Time frame: Baseline (Day -1) and Day 4
Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A SAE is defined as any untoward medical occurrence that, at any dose results in death,is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation according to medical or scientific judgement.
Time frame: Up to Week 11
Number of Participants With Clinically Significant Hematology Parameters
Blood samples were collected to analyze the following hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, hemoglobin, hematocrit, mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), percentage reticulocytes and red blood cell count. Data for clinically significant abnormal hematology parameters have been presented. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
Time frame: Baseline (Day -1)
Number of Participants With Clinically Significant Chemistry Parameters
Blood samples were collected to analyze the following clinical chemistry parameters: Potassium, calcium, sodium, creatinine, glucose, alkaline phosphatase, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Blood urea nitrogen (BUN), total and direct bilirubin, total protein and creatine kinase. Data for clinically significant abnormal clinical chemistry parameters have been presented. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
Time frame: Baseline (Day -1)
Number of Participants With Clinically Significant Urine Parameters
Urine samples were collected to analyze the following urinalysis parameters: specific gravity, potential of hydrogen (pH). Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
Time frame: Baseline (Day -1)
This was a Phase 1, open-label, non-randomized, single dose study in healthy adult participants conducted at a single center in the United Kingdom (UK) to assess the prototype liquid fomulations of dolutegravir (DTG) versus DTG dispersible tablets (reference).
| Milestone | Prototype A/DTG Reference/Prototype B |
|---|---|
| Started | 22 |
| Completed | 22 |
| Not completed | 0 |
| Milestone | Prototype A/DTG Reference/Prototype B |
|---|---|
| Started | 22 |
| Completed | 19 |
| Not completed | 3 |
| Withdrew: Withdrawal by subject | 3 |
| Milestone | Prototype A/DTG Reference/Prototype B |
|---|---|
| Started | 19 |
| Completed | 18 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
Blood samples were collected at indicated time points and pharmacokinetic (PK) analysis was performed. PK parameters were determined by non-compartmental methods.
| Hours*micrograms per milliliter | Prototype A | Prototype B | DTG Reference |
|---|---|---|---|
| Area Under the Plasma Concentration Time Curve From Time Zero to the Last Quantifiable Time Point (AUC[0-t]) for DTG | 11.9968 ± 22.7 | 13.7921 ± 20.5 | 12.1944 ± 22.7 |
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
| Hours | Prototype A | Prototype B | DTG Reference |
|---|---|---|---|
| Absorption Lag Time (Tlag) Following Administration of DTG | 0.0 (0 to 0) | 0.0 (0 to 0) | 0.0 (0 to 0) |
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
| Hours | Prototype A | Prototype B | DTG Reference |
|---|---|---|---|
| Time of Maximum Observed Concentration (Tmax) Following Administration of DTG | 1.50 (0.5 to 3.5) | 0.50 (0.5 to 2.0) | 0.75 (0.5 to 5.0) |
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
| Hours | Prototype A | Prototype B | DTG Reference |
|---|---|---|---|
| Time of Last Quantifiable Concentration (Tlast) Following Administration of DTG | 48.0000 (47.983 to 72.283) | 48.0333 (48.000 to 72.317) | 48.0000 (47.783 to 72.150) |
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
| Hours | Prototype A | Prototype B | DTG Reference |
|---|---|---|---|
| Elimination Half-life (t½) Following Administration of DTG | 13.6389 ± 17.5 | 14.5997 ± 19.1 | 13.5807 ± 20.9 |
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
| Per hour | Prototype A | Prototype B | DTG Reference |
|---|---|---|---|
| Apparent Elimination Rate Constant (Lambda z) Following Administration of DTG | 0.0508 ± 17.5 | 0.0475 ± 19.1 | 0.0510 ± 20.9 |
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
| Percentage of AUCex | Prototype A | Prototype B | DTG Reference |
|---|---|---|---|
| Percentage of AUC(0-inf) Extrapolated (%AUCex) Following Administration of DTG | 6.1049 ± 36.8 | 5.8582 ± 57.1 | 6.3086 ± 36.3 |
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
| Hours*micrograms per milliliter | Prototype A | Prototype B | DTG Reference |
|---|---|---|---|
| AUC From Time Zero to 24 Hours (AUC[0-24]) Following Administration of DTG | 9.2541 ± 16.4 | 10.2918 ± 15.8 | 9.2356 ± 18.7 |
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
| Hours*micrograms per milliliter | Prototype A | Prototype B | DTG Reference |
|---|---|---|---|
| AUC From Time Zero to 72 Hours (AUC[0-72]) Following Administration of DTG | 12.2645 ± 22.0 | 14.1062 ± 20.8 | 12.5289 ± 21.9 |
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
| Liters per hour | Prototype A | Prototype B | DTG Reference |
|---|---|---|---|
| Apparent Oral Clearance (CL/F) Following Administration of DTG | 0.7794 ± 23.0 | 0.6752 ± 21.8 | 0.7650 ± 23.8 |
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
| Micrograms per milliliter | Prototype A | Prototype B | DTG Reference |
|---|---|---|---|
| Last Quantifiable Concentration (Ct) Following Administration of DTG | 0.0398 ± 35.4 | 0.0412 ± 53.2 | 0.0421 ± 39.9 |
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
| Liters | Prototype A | Prototype B | DTG Reference |
|---|---|---|---|
| Apparent Oral Volume of Distribution (Vz/F) Following Administration of DTG | 15.3369 ± 13.8 | 14.2222 ± 15.0 | 14.9889 ± 19.1 |
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
| Micrograms per milliliter | Prototype A | Prototype B | DTG Reference |
|---|---|---|---|
| Concentration at 24hours Post-dose (C24) Following Administration of DTG | 0.1763 ± 28.5 | 0.2167 ± 21.7 | 0.1917 ± 22.7 |
SBP and DBP was measured in a supine position after at least 5 minutes of rest for the participant in a quiet setting without any distractions using a completely automated device. Day -1 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specific time point value.
| Millimeters of mercury | Prototype A | Prototype B | DTG Reference |
|---|---|---|---|
| SBP, Day 4 | 0.3 ± 10.50 | 4.9 ± 10.97 | 7.3 ± 9.59 |
| DBP, Day 4 | -0.7 ± 6.83 | 1.8 ± 6.07 | 7.8 ± 7.05 |
Pulse rate was measured in a supine position after at least 5 minutes of rest for the participant in a quiet setting without any distractions using a completely automated device. Day -1 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specific time point value.
| Beats per minute | Prototype A | Prototype B | DTG Reference |
|---|---|---|---|
| Change From Baseline in Pulse Rate | 6.1 ± 11.06 | 6.8 ± 8.54 | 4.1 ± 11.38 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A SAE is defined as any untoward medical occurrence that, at any dose results in death,is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation according to medical or scientific judgement.
| Participants | Prototype A | Prototype B | DTG Reference |
|---|---|---|---|
| Non-serious AEs | 3 | 3 | 4 |
| SAEs | 0 | 0 | 0 |
Blood samples were collected to analyze the following hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets, hemoglobin, hematocrit, mean corpuscular hemoglobin (MCH), mean corpuscular volume (MCV), percentage reticulocytes and red blood cell count. Data for clinically significant abnormal hematology parameters have been presented. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
| Participants | Prototype A | Prototype B | DTG Reference |
|---|---|---|---|
| Number of Participants With Clinically Significant Hematology Parameters | 0 | 0 | 0 |
Blood samples were collected to analyze the following clinical chemistry parameters: Potassium, calcium, sodium, creatinine, glucose, alkaline phosphatase, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Blood urea nitrogen (BUN), total and direct bilirubin, total protein and creatine kinase. Data for clinically significant abnormal clinical chemistry parameters have been presented. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
| Participants | Prototype A | Prototype B | DTG Reference |
|---|---|---|---|
| Number of Participants With Clinically Significant Chemistry Parameters | 0 | 0 | 0 |
Urine samples were collected to analyze the following urinalysis parameters: specific gravity, potential of hydrogen (pH). Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
| Participants | Prototype A | Prototype B | DTG Reference |
|---|---|---|---|
| Number of Participants With Clinically Significant Urine Parameters | 0 | 0 | 0 |
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
| Hours*micrograms per milliliter | Prototype A | Prototype B | DTG Reference |
|---|---|---|---|
| AUC From Time Zero to Infinity (AUC[0-inf]) for DTG | 12.8297 ± 23.0 | 14.8099 ± 21.8 | 13.0715 ± 23.8 |
Blood samples were collected at indicated time points and PK analysis was performed. PK parameters were determined by non-compartmental methods.
| Micrograms per milliliter | Prototype A | Prototype B | DTG Reference |
|---|---|---|---|
| Maximum Observed Concentration (Cmax) for DTG | 0.9200 ± 14.4 | 0.9993 ± 17.6 | 0.8200 ± 26.1 |
Collected over Non-serious and serious adverse events were collected up to Week 11. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Prototype A | 0/18 (0%) | 0/18 (0%) | 3/18 (16.7%) |
| Prototype B | 0/19 (0%) | 0/19 (0%) | 3/19 (15.8%) |
| DTG Reference | 0/22 (0%) | 0/22 (0%) | 4/22 (18.2%) |
| Event | Prototype A | Prototype B | DTG Reference |
|---|---|---|---|
| HeadacheNervous system disorders | 0/18 | 1/19 | 2/22 |
| Tension headacheNervous system disorders | 1/18 | 0/19 | 0/22 |
| DiarrhoeaGastrointestinal disorders | 1/18 | 0/19 | 0/22 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/18 | 0/19 | 0/22 |
| Arthropod biteInjury, poisoning and procedural complications | 0/18 | 1/19 | 0/22 |
| Skin abrasionInjury, poisoning and procedural complications | 0/18 | 1/19 | 0/22 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/18 | 1/19 | 0/22 |
| HordeolumInfections and infestations | 0/18 | 0/19 | 1/22 |
| Rash erythematousSkin and subcutaneous tissue disorders | 0/18 | 0/19 | 1/22 |
| Age, Continuous(Years) | Prototype A/DTG Reference/Prototype B |
|---|---|
| Mean | 31.3 ± 7.93 |
| Sex: Female, Male(Participants) | Prototype A/DTG Reference/Prototype B |
|---|---|
| Female | 0 |
| Male | 22 |
| Race/Ethnicity, Customized(Participants) | Prototype A/DTG Reference/Prototype B |
|---|---|
| CENTRAL/SOUTH ASIAN HERITAGE | 1 |
| BLACK OR AFRICAN AMERICAN | 2 |
| WHITE/CAUCASIAN/EUROPEAN HERITAGE | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from May 2019 to primary completion in Jul 2019, 2 months.
Results were first posted in Jul 2020, 1 year after primary completion.
Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 2 months is below that.
Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dolutegravir